GlassScriptPhysician profile
John Taylor Henson
NPI 1841293958
$2,857.50
in general payments reported to CMS, 2019-2025
23 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $139 · 2021: $91.52 · 2022: $468 · 2023: $599 · 2024: $446 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $521.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $482.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $380.23 | 2019-2025 | Otezla, Repatha |
| Pfizer INC. | $256.78 | 2019-2025 | |
| Abbvie INC. | $211.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $179.93 | 2019-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.12 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $103.18 | 2019-2023 | |
| Glaxosmithkline, LLC. | $100.33 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $88.42 | 2023-2025 | Cologuard Collection Kit |
| Baxter Healthcare | $81.18 | 2023 | Hillrom - Eli 280 |
| Abbott Laboratories | $59.94 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $41.23 | 2022 | |
| Dexcom, INC. | $39.70 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $35.73 | 2019-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.90 | 2019 | |
| Axsome Therapeutics, INC. | $23.29 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $22.42 | 2025 | Rexulti |
| Tandem Diabetes Care, INC. | $19.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.58 | 2022 | |
| Mannkind Corporation | $15.20 | 2023 | Afrezza |
| Currax Pharmaceuticals LLC | $14.32 | 2023 | Onzetra Xsail, Nexletol, Contrave |
| Idorsia Pharmaceuticals US INC | $13.06 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Henson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.